Evidence mapPaperPMID 16306358Full record

ArticleDiabetes2005

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

Hassan Rahmoune, Paul W Thompson, Joanna M Ward, Chari D Smith, Guizhu Hong, John Brown

3 registry-linked trialsOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetes, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 316 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
316citing papers in PubMed, 7 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02798744 phase4completedstarted 2016, after this paper: background citation

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)

Ran2016Enrolled68Registered outcomes15Posted comparisons0ConditionsDiabetes Mellitus, Type 2Armsdiet, empagliflozin, Placebo
Open the trial in the graph
NCT02887677 phase4terminatedstarted 2016, after this paper: background citation

A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes

Ran2016Enrolled85Registered outcomes9Posted comparisons0ConditionsDiabetes MellitusArmsdapagliflozin, Placebo
Open the trial in the graph
NCT05727423 unknown statusnot on this mapstarted 2021, after this paper: background citation

Safety and Efficacy of Dapagliflozin in the Treatment of Heart Failure in Non-diabetic Egyptian Patients

TypeobservationalSponsorHelwan UniversityRan2021 to 2024Enrolled45ConditionsHeart Failure
3 · Its place in the literature

Who cites it

316 citing papers in PubMed, 7 syntheses or guidelines pooled it, 763 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Influence of Dietary Salt Intake on T2D Treatment.Frontiers in endocrinology · 2022
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Salt and chronic kidney disease.Nature reviews. Nephrology · 2026
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

256 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hassan RahmouneClinical Pharmacology Unit, GlaxoSmithKline, Translational Medicine and Technology, Human Biomarkers Centre, Addenbrooke's Hospital, Cambridge, CB2 2GG, UK. hassan_2_rahmoune@gsk.com
Paul W Thompson
Joanna M Ward
Chari D Smith
Guizhu Hong
John Brown
GlaxoSmithKline (United Kingdom) · GBAddenbrooke's Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The bulk of glucose that is filtered by the renal glomerulus is reabsorbed by the glucose transporters of the proximal convoluted tubular epithelium. However, it has been difficult to investigate this in diseases such as type 2 diabetes because of the inability to isolate primary renal cells from patients without a renal biopsy. We report here a method for the immunomagnetic isolation and novel primary culture of human exfoliated proximal tubular epithelial cells (HEPTECs) from fresh urine. The primary isolates are highly enriched and differentiated and express characteristic proximal tubular phenotypic markers. They continue to express the proximal tubular markers CD13/aminopeptidase-N, sodium glucose cotransporter (SGLT) 2, and alkaline phosphatase through up to six subsequent subcultures in a similar way to human proximal cells isolated from renal biopsies. In a hyperglycemic environment, HEPTECs isolated from patients with type 2 diabetes expressed significantly more SGLT2 and the facilitative glucose transporter GLUT2 than cells from healthy individuals. We also demonstrated a markedly increased renal glucose uptake in HEPTECs isolated from patients with type 2 diabetes compared with healthy control subjects. Our findings indicate for the first time in a human cellular model that increased renal glucose transporter expression and activity is associated with type 2 diabetes.

Indexed as

Base SequenceBiological TransportDiabetes Mellitus, Type 2DNA PrimersEpithelial CellsGlucoseGlucose Transport Proteins, FacilitativeHumansKidney Tubules, ProximalMicroscopy, ConfocalPolymerase Chain ReactionUrineDNA PrimersGlucoseGlucose Transport Proteins, Facilitative

Identifiers

PMID16306358
OpenAlexW2155287847

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.